HbA1c and Diabetes Biomarkers: A Decade of Analytical and Clinical Progress
This review surveys the evolution of diabetes mellitus biomarkers over the past decade, centring on HbA1c while covering emerging non-invasive alternatives and complementary markers. The author addresses analytical standardisation, POCT-specific performance requirements, and the role of external quality assessment in maintaining measurement reliability. Special attention is given to how high-sensitivity methods and new biomarker candidates may refine diabetes diagnosis and monitoring beyond traditional glucose and HbA1c testing.
The original study
HbA
- Authors
- Gillery P
- Journal
- Clinical chemistry and laboratory medicine
- Type
- Journal Article, Review
- PMID
- 36239682
Original abstract
Since its discovery in the late 1960s, HbA1c has proven to be a major biomarker of diabetes mellitus survey and diagnosis. Other biomarkers have also been described using classical laboratory methods or more innovative, non-invasive ones. All biomarkers of diabetes, including the historical glucose assay, have well-controlled strengths and limitations, determining their indications in clinical use. They all request high quality preanalytical and analytical methodologies, necessitating a strict evaluation of their performances by external quality control assessment trials. Specific requirements are needed for point-of-care testing technologies. This general overview, which describes how old and new tools of diabetes mellitus biological survey have evolved over the last decade, has been built through the prism of papers published in Clinical Chemistry and Laboratory Medicine during this period.